Novembre 2023: Nivolumab (Opdivo, Bristol-Myers Squibb Company) was granted approval by the Food and Drug Administration as an adjuvant therapy for Stage IIB/C melanoma in patients 12 years of age and older who had undergone complete resection.
In the randomized, double-blind trial CHECKMATE-76K (NCT04099251), which included 790 patients with Stage IIB/C melanoma, efficacy was assessed. A placebo or 480 mg nivolumab was administered intravenously to patients in a randomized (2:1) fashion every four weeks for a maximum of one year, or until disease recurrence or unacceptable toxicity occurred.
A complete resection of the primary mélanome with negative margins and a negative sentinel lymph node within 12 weeks prior to randomization, as well as an ECOG performance status of 0 or 1, were prerequisites for enrollment. Patients who met the inclusion criteria for the trial did not have ocular/uveal or mucosal melanoma, autoimmune disease, any condition necessitating systemic treatment with corticosteroids (equivalent to or exceeding 10 mg of daily prednisone) or other immunosuppressive drugs, or prior melanoma therapy other than surgery. AJCC 8th staging system edition stratification of randomization was employed (T3b versus T4a versus T4b).
Le principal critère de jugement d'efficacité était la survie sans récidive (RFS), que les enquêteurs ont définie comme le temps écoulé entre la randomisation et le premier des événements suivants : récidive de métastases locales, régionales ou à distance, nouveau mélanome primaire ou mortalité (quelle qu'en soit la cause). ). Les évaluations ont été effectuées à intervalles de 26 semaines de la première à la troisième année, puis toutes les 52 semaines pendant les cinq années suivantes. Dans les bras nivolumab et placebo, la RFS médiane n'a pas été atteinte (IC à 95 % : 28.5, non atteint ; valeur p < 0.0001). Le rapport de risque était de 0.42 [IC à 95 % : 0.30, 0.59] ; La valeur p était inférieure à 0.0001.
Mood swings, musculoskeletal pain, pruritis, rash, and diarrhea were the most frequently reported adverse effects (>20% of patients).
Patients weighing 40 kg or more are advised to take 240 mg of nivolumab every 2 weeks or 480 mg every 4 weeks until disease progression or unacceptable toxicity, for a maximum of one year. For up to one year, pediatric patients weighing less than 40 kg are prescribed a dosage of 3 mg/kg every two weeks or 6 mg/kg every four weeks, until disease progression or unacceptable toxicity occurs.
